Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT03360747 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Familial Chylomicronemia Syndrome
Lipoprotein Lipase Deficiency
Hyperlipoproteinemia Type 1

Interventions

DRUG: AKCEA-ANGPTL3-LRx

Sponsor

Akcea Therapeutics

Collaborators

[object Object]